Science and Technology
publicado em 07/04/2011 às 03h00:00
   Dê o seu voto:

Approved new treatment for rare form of thyroid cancer

Vandetanib attacks the ability of medullary thyroid cancer to grow and expand and is administered orally in daily doses

 
font size
A-
A+

Some pieces of information on this page may have been automatically translated. Makernews is not responsible for the irregularities resulting from these translations. When in doubt,      consult the original text.



The drug regulatory agency and the U.S. Food Administration (FDA) approved drug administration Vandetanib to treat adult patients with advanced medullary thyroid cancer.

Vandetanib attacks the ability of medullary thyroid cancer to grow and expand. There is currently no FDA approved treatment for this cancer. Vandetanib is administered orally in daily doses.

The safety and efficacy of the drug have been established in a single randomized, international 331 patients with advanced medullary thyroid cancer. Patients in the study were selected to receive Vandetanib or placebo (sugar pill).

The study was designed to measure the length of time a patient survives without the cancer progressing. Patients who received Vandetanib had a period of survival without disease progression increased when compared with patients receiving placebo.

The median progression-free survival was 16.4 months in the placebo group and at least 22.6 months in the group receiving Vandetanib.

The researchers say it is too early to determine the average progression-free survival in patients treated with Vandetanib or to say whether they will live longer compared to patients treated with placebo.

"The approval Vandetanib underscores FDA's commitment to approve treatments for patients with rare and difficult to treat," said Richard Pazdur, FDA.

Common side effects that occur when using Vandetanib include diarrhea, rash, nausea, hypertension, headache, fatigue, decreased appetite. Serious side effects reported during the study resulted in five deaths in patients treated with Vandetanib. The causes of death were respiratory complications, heart failure, and a bacterial infection in the blood (sepsis).

Vandetanib has been shown to affect the heart's electrical activity, which in some cases can cause irregular heartbeats that can lead to death.

The drug is being approved with a Risk Evaluation and Mitigation Strategy (REMS) to inform health professionals about the serious risks of heart problems. Only pharmacies and health professionals certified through the program Vandetanib REMS, a restricted distribution program will be able to prescribe and deliver the drug.

Germany

Source: Isaude.net
   Palavras-chave:   Thyroid cancer    Medullary thyroid cancer    Vandetanib    FDA   
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: Approved new treatment for rare form of thyroid cancer
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: Approved new treatment for rare form of thyroid cancer


Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
thyroid cancer    medullary thyroid cancer    Vandetanib    FDA   
Comments:
Comment
Leave your comment
Close
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
advertising
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story: http://www.isaude.net
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaúde.net
Get the newsletter of the portal  iSaúde.net
Recommend the portal iSaúde.net
News from  iSaúde.net in your blog or website.
Get news on the subject of your interest.
© 2000-2011 www.isaude.net Todos os direitos reservados.